Involvement of Wild-type P53 in Pre-B-cell Differentiation in Vitro

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 1991 Oct 15

PMID 1924360

Citations 41

Authors

G Shaulsky

N Goldfinger

A Peled

V Rotter

Affiliations

Soon will be listed here.

Abstract

Wild-type p53 protein is a growth modulator whose inactivation has been found to be a key event in malignant transformation. Reconstitution of wild-type p53 in the p53-nonproducer, Abelson murine leukemia virus-transformed pre-B-cell line L12 gave rise to stably growing clones. Wild-type p53-producer derived cell lines exhibit an altered cell cycle, however. More cells with an extended G0/G1 phase were found than in the p53-nonproducer parental cell line. Furthermore, when injected into syngeneic mice, these cells induced a lower incidence of tumors and these tumors were less aggressive. Analysis of immunoglobulin expression revealed that wild-type p53 induced the expression of cytoplasmic immunoglobulin mu heavy chain. In addition, these derived cells lines exhibited increased levels of a B-cell-specific surface marker, B220. These results suggest that wild-type p53 may function as a cell differentiation factor that can induce development of pre-B cells into a more advanced stage in the pathway of B-cell maturation. In these pre-B cells, wild-type p53 may induce cell differentiation without terminal growth arrest of the cell population.

Citing Articles

Concepts in B cell acute lymphoblastic leukemia pathogenesis.

Garcia C, Miller-Awe M, Witkowski M J Leukoc Biol. 2024; 116(1):18-32.

PMID: 38243586 PMC: 11869204. DOI: 10.1093/jleuko/qiae015.

Tumor protein 53 mutations are enriched in diffuse large B-cell lymphoma with irregular CD19 marker expression.

Kazantseva M, Hung N, Mehta S, Roth I, Eiholzer R, Rich A Sci Rep. 2017; 7(1):1566.

PMID: 28484276 PMC: 5431468. DOI: 10.1038/s41598-017-01800-6.

Level of PAX5 in differential diagnosis of non-Hodgkin's lymphoma.

Bharti B, Shukla S, Tripathi R, Mishra S, Kumar M, Pandey M Indian J Med Res. 2016; 143(Supplement):S23-S31.

PMID: 27748274 PMC: 5080925. DOI: 10.4103/0971-5916.191747.

Genome-wide analysis of the p53 gene regulatory network in the developing mouse kidney.

Li Y, Liu J, McLaughlin N, Bachvarov D, Saifudeen Z, El-Dahr S Physiol Genomics. 2013; 45(20):948-64.

PMID: 24003036 PMC: 3798767. DOI: 10.1152/physiolgenomics.00113.2013.

Inflammation and insulin resistance exert dual effects on adipose tissue tumor protein 53 expression.

Ortega F, Moreno-Navarrete J, Mayas D, Serino M, Rodriguez-Hermosa J, Ricart W Int J Obes (Lond). 2013; 38(5):737-45.

PMID: 23999197 DOI: 10.1038/ijo.2013.163.

References

Rosenberg N, Baltimore D . A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J Exp Med. 1976; 143(6):1453-63. PMC: 2190217. DOI: 10.1084/jem.143.6.1453. View

Yewdell J, Gannon J, Lane D . Monoclonal antibody analysis of p53 expression in normal and transformed cells. J Virol. 1986; 59(2):444-52. PMC: 253095. DOI: 10.1128/JVI.59.2.444-452.1986. View

Coffman R, Weissman I . B220: a B cell-specific member of th T200 glycoprotein family. Nature. 1981; 289(5799):681-3. DOI: 10.1038/289681a0. View

Arai N, Nomura D, Yokota K, Wolf D, Brill E, Shohat O . Immunologically distinct p53 molecules generated by alternative splicing. Mol Cell Biol. 1986; 6(9):3232-9. PMC: 367060. DOI: 10.1128/mcb.6.9.3232-3239.1986. View

Munroe D, Rovinski B, Bernstein A, Benchimol S . Loss of a highly conserved domain on p53 as a result of gene deletion during Friend virus-induced erythroleukemia. Oncogene. 1988; 2(6):621-4. View

Eliyahu D, Goldfinger N, Shaulsky G, Skurnik Y, Arai N, Rotter V . Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene. 1988; 3(3):313-21. View

Hinds P, Finlay C, Levine A . Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol. 1989; 63(2):739-46. PMC: 247745. DOI: 10.1128/JVI.63.2.739-746.1989. View

Baker S, Fearon E, Nigro J, Hamilton S, Preisinger A, Jessup J . Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989; 244(4901):217-21. DOI: 10.1126/science.2649981. View

Finlay C, Hinds P, Levine A . The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989; 57(7):1083-93. DOI: 10.1016/0092-8674(89)90045-7. View

10.

Ahuja H, Bar-Eli M, Advani S, Benchimol S, Cline M . Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci U S A. 1989; 86(17):6783-7. PMC: 297930. DOI: 10.1073/pnas.86.17.6783. View

11.

Kelman Z, Prokocimer M, Peller S, Kahn Y, Rechavi G, Manor Y . Rearrangements in the p53 gene in Philadelphia chromosome positive chronic myelogenous leukemia. Blood. 1989; 74(7):2318-24. View

12.

Eliyahu D, Michalovitz D, Eliyahu S, Oren M . Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci U S A. 1989; 86(22):8763-7. PMC: 298370. DOI: 10.1073/pnas.86.22.8763. View

13.

Takahashi T, Nau M, Chiba I, Birrer M, Rosenberg R, Vinocour M . p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989; 246(4929):491-4. DOI: 10.1126/science.2554494. View

14.

Nigro J, Baker S, Preisinger A, Jessup J, Hostetter R, Cleary K . Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989; 342(6250):705-8. DOI: 10.1038/342705a0. View

15.

Lane D, Benchimol S . p53: oncogene or anti-oncogene?. Genes Dev. 1990; 4(1):1-8. DOI: 10.1101/gad.4.1.1. View

16.

Addison C, Jenkins J, Sturzbecher H . The p53 nuclear localisation signal is structurally linked to a p34cdc2 kinase motif. Oncogene. 1990; 5(3):423-6. View

17.

Gannon J, Greaves R, Iggo R, Lane D . Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990; 9(5):1595-602. PMC: 551855. DOI: 10.1002/j.1460-2075.1990.tb08279.x. View

18.

Beckmann H, Su L, Kadesch T . TFE3: a helix-loop-helix protein that activates transcription through the immunoglobulin enhancer muE3 motif. Genes Dev. 1990; 4(2):167-79. DOI: 10.1101/gad.4.2.167. View

19.

Nelsen B, Kadesch T, Sen R . Complex regulation of the immunoglobulin mu heavy-chain gene enhancer: microB, a new determinant of enhancer function. Mol Cell Biol. 1990; 10(6):3145-54. PMC: 360679. DOI: 10.1128/mcb.10.6.3145-3154.1990. View

20.

Libermann T, Lenardo M, Baltimore D . Involvement of a second lymphoid-specific enhancer element in the regulation of immunoglobulin heavy-chain gene expression. Mol Cell Biol. 1990; 10(6):3155-62. PMC: 360680. DOI: 10.1128/mcb.10.6.3155-3162.1990. View